U.S. markets closed
  • S&P 500

    4,163.29
    -10.56 (-0.25%)
     
  • Dow 30

    34,327.79
    -54.34 (-0.16%)
     
  • Nasdaq

    13,379.05
    -50.93 (-0.38%)
     
  • Russell 2000

    2,227.12
    +2.49 (+0.11%)
     
  • Crude Oil

    66.29
    +0.02 (+0.03%)
     
  • Gold

    1,866.40
    -1.20 (-0.06%)
     
  • Silver

    28.33
    +0.07 (+0.25%)
     
  • EUR/USD

    1.2158
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • GBP/USD

    1.4141
    +0.0004 (+0.03%)
     
  • USD/JPY

    109.1900
    -0.0100 (-0.01%)
     
  • BTC-USD

    42,818.02
    -2,951.06 (-6.45%)
     
  • CMC Crypto 200

    1,195.01
    -2.91 (-0.24%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Vanda files for approval of sleep disorder drug

WASHINGTON (AP) -- Vanda Pharmaceuticals has filed for marketing approval of tasimelteon, which is designed to treat a sleep disorder that affects blind people.

The drug is intended to treat a condition called non-24-hour disorder. Patients can't synchronize their bodies with the 24-hour cycle because they can't detect light.

The company says between 65,000 and 95,000 people in the U.S. have non-24-hour disorder, and there are no approved drugs to treat the condition.

Shares of Vanda Pharmaceuticals Inc. closed at $9.20 on Thursday, and gained 54 cents, or 5.9 percent, to $9.74 in premarket trading. That put the stock on pace to open their highest price in more than two years.